IVZ — Invesco Ltd.

Sentiment has turned positive after Q2 2026 adjusted EPS of $0.71 beat estimates, revenue of $1.82 billion beat consensus, and the company raised its growth profile with the launch of Invesco Solutions & Custom Strategies. As of 2026-08-27 the stock is up more than 50% over the last year, touching a new 52-week high, and several analysts have raised price targets—even though the official consensus rating remains Hold.

Revenue has been steadily climbing from $1.44B in Q3 2023 to $1.83B in Q2 2026, with YoY growth inflecting sharply higher: Q2 2025 grew only ~2.2% YoY, but Q1 2026 grew ~14.1% and Q2 2026 grew ~20.5% YoY. Reported earnings are distorted by massive non-cash impairments in Q4 2023 and Q4 2025—Q4 2025 had a -$1.06B net loss and -$2.61 EPS—but underlying operating margins are expanding, from ~14.1% in Q2 2025 to ~20.0% in Q2 2026. Free cash flow is strong too: Q2 2026 FCF of $720M was the best quarter in the dataset, and TTM FCF is roughly $1.94B.

On trailing GAAP earnings, the P/E is meaningless at -49x due to the Q4 2025 impairment. On forward numbers, IVZ trades at about 11.8x consensus FY estimated EPS of $2.812, a hair above its own 5-year average P/E of 11.48. P/S of 2.14 is above the 5-year average of 1.50, but that is more justified given the sharp revenue acceleration and margin recovery. P/B of 1.21 and a 2.6% dividend yield keep the stock from looking expensive; overall, valuation is fair rather than cheap.

The market is no longer valuing IVZ on its impaired trailing earnings; it is paying roughly 11.9x next year's normalized EPS. That means the easy multiple-re-rating from hated to respected is mostly done—upside from here has to come from actual earnings delivery, further estimate revisions, or better-than-expected inflows. The stock trading right at the consensus price target of ~$33.30 suggests the market is pricing a successful normalization but not a dramatic breakout.

As of 2026-08-27, RSI stood at 66.72, which is strong but getting close to overbought territory. Price was 4.2% above the 20-day SMA, 11.7% above the 50-day SMA, and 23.5% above the 200-day SMA, so the trend is clearly up and broad-based. For investors not already positioned, chasing the stock here is less attractive than waiting for a pullback toward the 20-day or 50-day SMA, but there is no technical sign of a trend break yet.

• Interest-rate path: higher-for-longer cash yields have been driving money-market inflows; a shift toward rate cuts could rotate assets into higher-margin equities and fixed income strategies.
• Private-markets push: Invesco is trying to narrow the valuation gap with alternative-asset managers by scaling custom multi-asset and private-market solutions, an industry-wide growth trend.
• High equity beta of 1.60 means IVZ's AUM, revenue, and earnings are amplified by broad market moves in both directions.
• Ongoing fee compression in active public equities remains a structural headwind to advisory fees and operating margins.
• Consolidation and competition: passive managers and alternatives specialists keep pressuring traditional asset managers on price and distribution.

• Q3 2026 earnings in late October 2026—the market will focus on net long-term inflows and whether the new Solutions & Custom Strategies platform is generating fee-paying traction.
• Monthly preliminary AUM updates, which will show whether money-market assets are rotating into higher-margin equities and alternatives.
• Further analyst price-target revisions if Q2 momentum extends into Q3.
• Stabilization or recovery of the real estate fund franchise after the 20% fee cut.

• A broad equity market correction would hit AUM, fee revenue, and earnings hard given the stock's 1.60 beta.
• Active-management fee compression in public equity and fixed income strategies is structural and ongoing.
• Execution risk in private markets and custom solutions: if the new strategy doesn't produce durable inflows, the current re-rating could stall.
• Large non-cash impairments—like the Q4 2023 and Q4 2025 write-downs—can keep reported earnings volatile and periodically spook investors.
• The stock is already at its average analyst price target, leaving limited headroom unless estimates move higher.

As of 2026-08-27, Invesco is a fundamentally solid but not screaming-cheap asset manager. The core story is improving—revenue growth accelerated to 20% YoY, underlying operating margins are in the high-teens to 20%, FCF is strong, and the dividend is covered by forward earnings. I lean bullish, but the stock is not a low-risk entry at $33.31, so buying on dips toward the 20-day or 50-day moving average would offer a better risk/reward.

I applied a 12.5x forward P/E to consensus next-FY EPS of $2.812, which is a justified premium to Invesco's historical average P/E of ~11.5x because revenue growth has accelerated to roughly 20% YoY and free cash flow is strong. That calculation yields a fair value of $35.15, independent of the consensus target.